China Shineway Pharmaceutical Group Limited (CSWYF)
ValueMarkers Composite Index
98% below intrinsic value ($6)
China Shineway Pharmaceutical Group Limited (CSWYF) — VMCI valuation read
CSWYF prints VMCI 73/100 inside the Healthcare sector, where the median sits at 50. The 23-point above-median delta is the cleanest single-number summary of China Shineway Pharmaceutical Group Limited's composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.
On CSWYF, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** CSWYF trades at 26.0x earnings, 44% above the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of -1.9x leaves covenant headroom; that is the risk line for China Shineway Pharmaceutical Group Limited on the trailing financials.
CSWYF fell 2.7% over the trailing 7 days, with a -18.3% read on a 30-day basis.
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.